Boundless Bio opened lower at $2.45, compared with its previous close of $2.46. In the last trading session, the stock traded between $2.42 and $2.47. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Boundless Bio is now worth
$ 17.31
Resulting in a loss of
$ 82.69 (82.69%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.01 (+0.24%)
Day High
$2.47
Day Low
$2.42
Day Open
$2.45
Prev Close
$2.46
Volume
26,844
1W Return
2.32%
1M Return
-2.84%
3M Return
-10.13%
6M Return
59.10%
1Y Return
95.71%
Fundamentals
Market Cap ($ Mn)
58
PE Ratio
-
PB Ratio
0.97
PEG Ratio
-
ROE
-47.03%
ROCE
-37.17%
EPS (TTM)
$-0.23
Investment Returns
1 Week
2.32%
1 Month
-2.84%
3 Months
-10.13%
6 Months
59.10%
9 Months
122.16%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
3Jul
Halper Sadeh investigates BOLD and NDRA merger deals
Halper Sadeh LLC is investigating potential breaches of fiduciary duties by Boundless Bio and ENDRA Life Sciences regarding their proposed mergers with Serapha Bio and Noble Africa LLC, respectively. Boundless Bio shareholders are expected to own approximately 3.7% of the combined company, while ENDRA shareholders are expected to own approximately 3%. The firm may seek increased consideration or additional disclosures for affected shareholders.
4mo ago
24Jun
Monteverde investigates Boundless Bio merger fairness
Monteverde & Associates PC is investigating the proposed merger of Boundless Bio, Inc. and Serapha Bio, Inc. to assess if Boundless Bio shareholders are receiving fair consideration. The all-stock transaction leaves Boundless shareholders with 3.7% ownership, supported by a $230 million private placement and a projected $44-$48 million dividend. The combined entity, trading as Serapha Bio, aims to advance SERP-01 through Phase 2 and into Phase 3 trials.
